scholarly journals Granulocyte Colony-Stimulating Factor Induces Osteoblast Inhibition by B Lymphocytes and Osteoclast Activation by T Lymphocytes during Hematopoietic Stem/Progenitor Cell Mobilization

2015 ◽  
Vol 21 (8) ◽  
pp. 1384-1391 ◽  
Author(s):  
Sidan Li ◽  
Tianshou Li ◽  
Yongbing Chen ◽  
Yinchao Nie ◽  
Changhong Li ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
B Lymphocytes ◽  
Progenitor Cell ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Hematopoietic Stem ◽  
Osteoclast Activation ◽  
Cell Mobilization ◽  
Stimulating Factor

Progenitor cell mobilization by granulocyte colony-stimulating factor controlled by loci on chromosomes 2 and 11

Blood ◽  
2000 ◽  
Vol 95 (5) ◽  
pp. 1872-1874 ◽  
Author(s):  
Masakazu Hasegawa ◽  
Tracey M. Baldwin ◽  
Donald Metcalf ◽  
Simon J. Foote
Keyword(s):  
Inbred Mice ◽  
Chromosome 2 ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Chromosome 11 ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Trait Locus ◽  
Cell Mobilization ◽  
Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF) can effectively mobilize hematopoietic stem and progenitor cells from bone marrow into blood, thereby allowing peripheral blood stem cells (PBSCs) to be used for transplantation. The efficiency of PBSC mobilization response to G-CSF is a multigene trait. DBA/2 (high-responder) and C57BL/6 (low-responder) mice were used for a genetic analysis of G-CSF–induced progenitor release. Significant linkages were found on chromosome 2 by analyzing segregation distortion among the high responders of 500 backcross mice and on chromosome 11 by using the quantitative trait locus analysis of 26 strains of BXD recombinant inbred mice.

Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs).

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1900-1900
Author(s):  
Chitra Hosing ◽  
Mark Munsell ◽  
Uday Popat ◽  
Martin Körbling ◽  
Rosamar Valverde ◽  
...  
Keyword(s):  
Success Rate ◽  
Clinical Outcomes ◽  
Progenitor Cell ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Hematopoietic Progenitor ◽  
Gm Csf ◽  
Cell Mobilization ◽  
Stimulating Factor ◽  
Graft Composition

Abstract Both G-CSF and GM-CSF (alone or in combination) may be used for mobilization of hematopoietic progenitor cells in patients undergoing autologous stem cell transplantation (ASCT). It has been suggested that GM-CSF use during mobilization may impact graft composition and therefore clinical outcomes. METHODS: We prospectively evaluated patients ≤ 70 years old with relapsed CD20+ NHL who were candidates for ASCT. Additional eligibility criteria included adequate marrow and organ function. Patients with history of pelvic radiation, > 3 prior chemoregimens or > 6 cycles of fludarabine chemotherapy were excluded. Patients recieved chemotherapy with ifosfamide 3.33 g/m2 daily × 3 days, etoposide 150 mg/m2 × 6 doses and rituximab (375 mg/m2 on day 1 and 1 g/m2 on day 8). Using a Bayesian adaptive randomization based on treatment outcomes, patient’s were randomized to receive G-CSF 12 μg/kg/d (Group G) or G-CSF 12 μg/kg/d plus GM-CSF 500 μg/d (Group G/GM). We assumed that the success rate for each treatment arm had a β prior distribution with mean 0.90 and variance 0.03. Cytokines started 24 hours after completion of chemotherapy and continued until completion of apheresis. RESULTS: Forty-three patients were randomized to Group G and 41 patients to Group G/GM. In each arm 1 patient withdrew consent after randomization. Baseline characteristics were similar in the 2 groups (Table 1). Both regimens were equally well tolerated. Data are presented as intent to treat analysis. Thirty-nine patients (90.7%) in Group G and 35 patients (85.4%) in Group G/GM collected ≥ 4 × 106 CD34+ cells/kg. The probability that Group G has a higher success rate than Group G/GM is 0.778. The median CD34+ cell dose collected was 10.3 × 106/kg (range, 0.1–59) and 7.5 × 106/kg (range, 0.7–73) in Groups G and G/GM respectively (P=NS). A median of 2 apheresis procedures were required in both arms. Seventy-three patients have undergone ASCT. After a median follow up time of 14.5 months (range, 0.6–38.5) in Group G and 14.0 months (range, 1.1–39.9) in Group G/GM, the 3 year PFS is 75% (95% CI 57.9–99.4) and 77% (95% CI 65–91.5) respectively (P=0.41). CONCLUSION: Our study does not support the hypothesis that using G-CSF plus GM-CSF versus G-CSF alone for progenitor cell mobilization alters graft composition in a way that impacts clinical outcomes after ASCT for NHLs. Baseline Patient Characteristics *Missing data 1 patient G-CSF, N (%) G-CSF + GM-CSF, N (%) 43 (51) 41 (49) AGE <39 4 (9.3) 3 (7.3) 40–59 29 (57.4) 26 (63.5) >59 10 (23.2) 12 (29.3) GENDER (Male/Female) 29/14 (67.4/32.6) 24/17 (58.5/41.5) HISTOLOGY Low grade 4 (9.3) 7 (17.1) Intermediate grade 39 (90.7) 34 (82.9) ANN ARBOR STAGE >I 18 (41.9) 18 (43.9) LDH>Normal* 15 (34.9) 11 (27.5) Figure Figure

scholarly journals Effects of granulocyte–colony-stimulating factor on progenitor cell mobilization and heart perfusion and function in normal mice

Cytotherapy ◽  
2011 ◽  
Vol 13 (2) ◽  
pp. 237-247 ◽  
Author(s):  
Marie Delgaudine ◽  
Bernard Lambermont ◽  
Patrizio Lancellotti ◽  
Véronique Roelants ◽  
Stéphan Walrand ◽  
...  
Keyword(s):  
Progenitor Cell ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Heart Perfusion ◽  
Cell Mobilization ◽  
And Function ◽  
Stimulating Factor
Sign in / Sign up

Export Citation Format

Share Document